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Background: Integrins and enzymes of the eicosanoid pathway are both well-established contributors to cancer.
However, this is the first report of the interdependence of the two signaling systems. In a screen for proteins that
interacted with, and thereby potentially regulated, the human platelet-type 12-lipoxygenase (12-LOX, ALOX12), we
identified the integrin β4 (ITGB4).
Methods: Using a cultured mammalian cell model, we have demonstrated that ITGB4 stimulation leads to recruitment
of 12-LOX from the cytosol to the membrane where it physically interacts with the integrin to become enzymatically
active to produce 12(S)-HETE, a known bioactive lipid metabolite that regulates numerous cancer phenotypes.
Results: The net effect of the interaction was the prevention of cell death in response to starvation. Additionally,
regulation of β4-mediated, EGF-stimulated invasion was shown to be dependent on 12-LOX, and downstream Erk
signaling in response to ITGB4 activation also required 12-LOX.
Conclusions: This is the first report of an enzyme of the eicosanoid pathway being recruited to and regulated by
activated β4 integrin. Integrin β4 has recently been shown to induce expansion of prostate tumor progenitors and
there is a strong correlation between stage/grade of prostate cancer and 12-LOX expression. The 12-LOX enzymatic
product, 12(S)-HETE, regulates angiogenesis and cell migration in many cancer types. Therefore, disruption of integrin
β4-12LOX interaction could reduce the pro-inflammatory oncogenic activity of 12-LOX. This report on the consequences
of 12-LOX and ITGB4 interaction sets a precedent for the linkage of integrin and eicosanoid biology through direct
protein-protein association.
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The human β4 integrin subunit was identified as a 12-LOX-
interacting protein, and thus a potential 12-LOX regulator
[1]. Integrins are multi-domain glycoproteins that promote
cellular adhesion, and coordinate growth and differentiation
signals. The β4 integrin subunit is part of a cell surface
receptor (α6β4) for laminin (LN), an extracellular matrix
component. Ligation of this surface receptor by LN or by an
activating antibody (3E1), triggers signaling pathways
involved in cell proliferation, differentiation, apoptosis,
adhesion, invasion and metastasis [2]. β4 impacts angiogen-
esis [3], anchorage-independent growth [4], cell survival [5],* Correspondence: k.v.honn@wayne.edu
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unless otherwise stated.cellular invasion [6], and tumor progression [7]. Integrin β4
is associated with increased cancer aggressiveness [8],
which is likely due to its ability to cooperate with other
receptors [9–12].
12-Lipoxygenase is associated with many of the same
β4-mediated phenotypes [13], and also promotes tumor cell
survival. Lipoxygenases (LOX) are a family of non-heme
iron-containing dioxygenases that stereo specifically insert
molecular oxygen into 1,4-cis, cis-pentadiene-containing
polyunsaturated fatty acids to ultimately produce bio-
active lipids such as leukotrienes, lipoxins, jasmonates
and 12-hydroxyeicosatetraenoic acid [12(S)-HETE] that
regulate numerous biological and pathological pro-
cesses [13, 14]. The platelet-type 12-LOX (P-12-LOX)
is one of three mammalian 12-LOX isoforms (classified as
platelet-, leukocyte-, or epidermal-type) that differ in tissuehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and is notably elevated in a variety of human tumors where
it is anti-apoptotic [15, 16]. In a clinical study, 38 %
of the prostate cancer patients studied (n = 132)
exhibited elevated levels of P-12-LOX in cancer tissues,
which correlated positively with tumor stage, grade
and positivity for prostate cancer cells in the surgical
margins [17].
12-LOX metabolizes arachidonic acid (AA) exclusively
to 12(S)-HETE [18]. This metabolite is intimately linked
to tumor progression and metastasis as well as to other
pathological conditions, such as psoriasis, atherosclerosis
and arthritis [13, 19–21]. 12(S)-HETE modulates integrins
(e.g., αvβ3), regulates secretion of proteinases, enhances
tumor cell motility and invasion, and induces angiogenesis
[13, 22, 23], which represent traits that are also regulated
by ITGB4. 12-LOX enzymatic activity is also regulated by
subcellular compartmentalization, and there is precedent
for the enzymatic activity of other lipoxygenases, namely
5-LOX and 15-LOX, being compartment-dependent [24,
25]. In the present study we utilized a cell culture model
to characterize both the physical interactions between
12-LOX and the β4 integrin subunit and the functional
outcomes of these interactions. This is the first report of
an integrin regulating an enzyme of an eicosanoid
biosynthetic pathway, and suggests a new paradigm for
both integrin and eicosanoid biology.
Results
The cytoplasmic domain of β4 interacts with 12-LOX in
tumor cells
The A431 human epidermoid carcinoma cell line has
been widely used to study 12-LOX, as it expresses
enzymatically active 12-LOX protein, but not the
leukocyte-type isoform [24]. Previously we reported that
12-LOX interacts with the C-terminal cytoplasmic domain
of the integrin β4 subunit in a yeast-two hybrid screen of
an A431 library [1]; an interaction that was validated in
the parental A431 cells and 12-LOX over-expressing
transfectants. We performed a co-immunoprecipitation
assay to examine the endogenous interaction of 12-LOX
with β4. Cells were stimulated with an antibody to
the extracellular domain of β4 subunit (3E1), and
β4-associated proteins were subsequently immunoprecipi-
tated from extracts using antibodies that either recognized
the extracellular domain (3E1, 439-9B) or the cytoplasmic
domain of β4 (450-11A), and these were probed for the
presence of 12-LOX. In reciprocal experiments, following
stimulation with 3E1, samples were first immunoprecipi-
tated with anti-12-LOX antibody, and then probed for β4
association. In A431 cells and A431 12-LOX transfectants
(Additional file 1), we detected 12-LOX immunoprecipi-
tated with a mAb to β4 (Fig. 1A, left panels). Conversely
β4 was immunoprecipitated with an antibody to 12-LOX(Fig. 1A, right panels). The association of 12-LOX with β4
was time-dependent beginning at 5 min post stimula-
tion. These data suggest that the interaction between
12-LOX and β4 originally discovered in the yeast 2-hybrid
model system also occurs in a cultured human tumor
cell model.
We tested this interaction in CHO cells that express
α6β1 and low levels of 12-LOX, but not β4 [26]. After con-
firming ectopic co-expression of β4, or truncated β4, with
12-LOX from cDNA constructs in CHO cell transfectants,
we found that 12-LOX co-immunoprecipitated with β4,
and vice versa (Fig. 1B, upper and lower panel, respectively.
lane 3-CHO transfectants producing full-length, wild-type
β4 alone, or lane 4-in combination with 12-LOX).
Full-length β4 was recognized by antibodies to both its
extracellular (3E1 mAb) and cytoplasmic (450-11A mAb)
domains. 12-LOX also co-immunoprecipitated with trun-
cated, head-less β4 (Fig. 1B, lane 5, upper and lower panel),
but not with truncated, tail-less integrin β4 (Fig. 1B, lane 6,
upper and lower panel). While truncated, tail-less β4
(95 kDa) complexes with α6 [26], in transfectants with tail-
less β4, 12-LOX did not co-immunoprecipitate with the
mAb to the cytoplasmic domain of the β4 (450-11A) or
with either mAb to the extracellular domain of β4, namely
3E1 or 439-9B (Fig. 1B lane 6, upper and lower panel). In
contrast, in transfectants expressing truncated, headless β4,
12-LOX co-immunoprecipitated with the 130-kDa trun-
cated β4, which was detectable with the 450-11A mAb to
the cytoplasmic tail (Fig. 1B, lane 5, lower panel), but not
with mAbs 3E1 or 439-9B. These findings suggest
that 12-LOX associates with the cytoplasmic domain
of β4 and that it interacts with β4 when the two proteins
are ectopically expressed in CHO cells. The differential
immunoprecipitation of 12-LOX with the panel of β4
constructs suggests that the cytoplasmic domain of β4 is
crucial for its interaction with 12-LOX, thus confirming
our earlier yeast two-hybrid results and those observed
with endogenous β4 in A431 cells.
Integrin β4 was detected in Western blots at the expected
molecular mass of 200 kDa. Interestingly, two minor bands
of 135 and 170 kDa from immunoprecipitates of 12-LOX
from both A431 cells and CHO transfectants were also
detected with β4 antibodies when the Ca2+ concentration
in the lysis buffer was high, which is in agreement with a
previous report [26] that suggested the cytoplasmic domain
of β4 is susceptible to a calcium-dependent protease
present in cellular extracts. Sequence analysis reveals two
calpain cleavage (PEST) sites that could result in the minor
bands we detected.
Finally, to verify the report that the mAb 3E1 func-
tionally stimulates β4 as well as laminin, the natural
ligand, immunoprecipitation was done with 12-LOX
antibody on laminin-treated cells with similar results
Fig. 1C.
Fig. 1 P-12-lipoxygenase interacts with integrin β4 subunit in vitro. (a) A431 cells were stimulated with mAb β4 3E1 and harvested at timed
intervals from 5–90 min. 12-LOX and the β4 subunit co-immunoprecipitated from untransfected A431 cells (A431), [and A431 cells over expressing
12-LOX (Tx-A431)-Additional file 1]. (b) CHO cells were transfected with different β4 constructs either alone or in combination with 12-LOX: (1) control:
vector alone; (2) CHO: nontransfected cells; (3) Txβ4: full-length β4; (4) Txβ4 + 12-LOX: cotransfected with full-length β4 and 12-LOX; (5) Txtruncated1:
pCMV-β4 Δ70-660 (c-myc tagged head-less) +12-LOX; (6) Txtruncated2: pCMV-β4 Δ854-1752 (tail-less) +12-LOX. 12-LOX and the β4 subunit
coimmunoprecipitated from three transfectants: Txβ4, Txβ4 + 12-LOX, and Txtruncated1 (headless). Positions of 12-LOX and β4 are indicated. The
experiment was repeated three times. For each experiment, mouse or rabbit IgG (control 1) and Sepharose 4B-conjugated protein G beads alone
(control 2) were used as negative controls. (C) 12-LOX and the β4 subunit co-immunoprecipitated from A431 cells after growth on laminin at the
same timed interval as with mAb 3E1 stimulation. Whole cell lysate of A431 stimulated with mAB 3E1 was loaded as a control (A431-3E1T). β4 subunit
was detected with mAb 450-11A
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Previous studies demonstrated that EGF, Ca2+ and the
phorbol ester TPA (12-O-tetradecanoylphorbol-13-acetate)
increased 12-LOX activity by inducing its translocation
from cytosol to membrane [24, 25, 27]. We examined
whether β4 interaction altered translocation of 12-LOX in
A431 cells where β4 was stimulated with 3E1 mAb for 5,
15, 30, 60 and 90 min. Membrane translocation of 12-LOX
from cytosol was observed within 5 min, peaked by 15 min,
and was sustained for 60 min (Fig. 2A). Thereafter theFig. 2 β4 ligation-induced translocation of 12-LOX in A431 cells. A431 cells
translocation of 12-LOX from cytosol to membrane. (b) The effect of β4 sti
detectable in whole cell lysates (WCL), but does not interact with 12-LOX oresponse was down-regulated. The effect of β4 stimulation
on 12-LOX translocation was specific as β1 stimulation
with activating antibody (Fig. 2B) failed to induce any
significant increase in membrane-associated 12-LOX.
Furthermore, while detectable in whole cell lysates,
β1 did not interact with 12-LOX on β4 stimulation
(Fig. 2C). In all experiments, total 12-LOX protein level
was unaltered after treatment with any of the antibodies
used in this study (Fig. 2, upper panels-Total). The bio-
chemistry was validated with confocal immunofluorescencestimulated with 3E1 mAb for 5, 15, 30, 60 and 90 min. (a) Membrane
mulation on 12-LOX translocation is specific to β4. (c) β1 integrin is
n β4 stimulation
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Additional file 5, Additional file 6 and Additional file 7).
Collectively these results demonstrate for the first time
that β4 ligation induces the translocation of 12-LOX from
cytosol to membrane where the two proteins interact.
The interaction of β4 with 12-LOX upregulates 12-LOX
enzymatic activity
To study whether 12-LOX activity is altered following
translocation to β4, its enzymatic activity was determined
by LC/MS (Fig. 3) or RP-HPLC (Additional file 8) analyses
for its sole arachidonate metabolite, 12(S)-HETE. LC/MS
measurements of total cellular and secreted 12(S)-HETE
were made. As with the isolated membrane fractions,
there is an accumulation of 12(S)-HETE metabolite with
3E1 stimulation (Fig. 3). Cytosolic and membrane protein
fractions were isolated from A431 cells following 5,
15, 30, 60 and 90 min treatment with 3Ε1 or control
IgG. Subsequently each fraction was incubated with
10 μM [14C] AA in DMEM, followed by lipid extraction
as described. In accordance with a previous study [24],
RP-HPLC analysis indicated that 12(S)-HETE was the
major product formed from exogenous AA in these
subcellular fractions, whereas other HETEs includingFig. 3 LC-MS analysis of 12-LOX activity. Following the stimulation with mA
was harvested and incubated in DMEM at 37 °C with 10 μM [14C]-AA for 15
and Methods. The data were analyzed by LC-MS in triplicate and error bars5-HETE and 15-HETE were not detected under our
conditions (Additional file 8a). Of the total 12-LOX
activity, 75 ± 6 % (mean ± s.d.; n = 3) resided in the
membrane fraction (100,000 x g-pellet), 20 ± 9 % in the
10,000 × g-pellet, and only 5 ± 1.2 % in the cytosolic
fraction. β4 ligation increased membrane-bound 12-LOX
and enhanced its activity in a time-dependent manner,
starting at 5 min and peaking at 60 min when 12(S)-HETE
production was 4–5 fold higher than control (mouse IgG)
(Additional file 8b). In agreement with the membrane
translocation experiment, 12(S)-HETE production also
declined 60 min post β4 mAb stimulation. Therefore,
recruitment of 12-LOX to the β4 subunit appears to
stimulate enzymatic activity and provides rationale for our
earlier observations that membrane-associated 12-LOX
was the dominant enzymatically active form in A431
tumor cells [24].
Activation of 12-LOX by β4 stimulation blocks A431 cells
from apoptosis induced by 12-LOX inhibitor
Lipoxygenase metabolites may act as survival factors in a
variety of tumor cells, as has been suggested [28]. As the
interaction of 12-LOX with the cytoplasmic domain of
β4 led to elevated levels of 12(S)-HETE, we exploredb β4 over a time course, each membrane fraction (100,000 × g pellet)
min. Cell lipids were extracted and analyzed as described in Materials
represent SEM
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survival. A DNA laddering assay revealed that pharma-
cological inhibition of 12-LOX with BMD122 induced
apoptosis in A431 cells in a dose-dependent manner,
similar to the effects found in an earlier study with
W256 cells [28] (Fig. 4B). This suggests that 12-LOX is
anti-apoptotic in A431 cells. Compared to parental A431
cells, or vector controls, only 12-LOX transfectants wereFig. 4 mAb β4 treatment effect on BMD122-induced apoptosis in
A431 cells by DNA laddering assay. (a) Comparison of A431 12-LOX
transfectants with empty vector control (3.1+). Cells were treated
with BMD122 (formerly BHPP) at the concentration indicated for 24 h,
low molecular weight DNA was extracted, run on a 1.5 % agarose gel
and visualized with ethidium bromide. The middle lanes are DNA
markers for comparison. 3.1+: empty vector controls; 12LOX: A431 cells
transfected with full-length 12-LOX. (b) A431 cells were pretreated with
mAb β4 3E1 (5 μg/ml) before incubation in DMEM in the presence of
BMD122, see details in Materials and Methods. Aliquots of DNA extracts
were subjected to 1.5 % agarose gel and visualized with ethidium
bromide. C: Ethanol as vehicle control. M: DNA marker, left lanemore resistant to apoptosis induced by BMD122 as shown
by the density of the DNA ladder (Fig. 4A). Pre-incubation
of A431 cells with mAb β4 3E1 for two hours prior to the
treatment with BMD122 (Fig. 4B), completely prevented
cells from undergoing BMD122-triggered apoptosis at low
BMD122 concentrations and significantly protected cells
exposed to high dose BMD122 (Fig. 4B). Both ELISA
detection of cytoplasmic nucleosomes [29] and Trypan
blue-exclusion ([30] and references therein) were employed
as an alternate measure of cell death (Additional file 9 and
Additional file 10).
12-LOX activation by β4 mediates EGF-stimulated
migration of A431 cells
EGF enhances α6β4-dependent cell migration of A431
cells on laminin [31]. As 12-LOX interacts physically and
functionally with β4 in A431 cells, we tested whether
12-LOX modulates integrin-dependent migration on
laminin or Matrigel. We demonstrated that EGF induced
A431 cells, preincubated with 3E1, to migrate on laminin
by 2–2.5 fold, and inhibition of 12-LOX by pretreatment
of cells with specific inhibitors (i.e., CDC, baicalein, or
BMD122) reduced A431 cell migration to the level
observed in the absence of EGF stimulation (Fig. 5A).
Laminin and 3E1 antibody induced migration through
Matrigel equally well (Fig. 5B-D). However, the inhibi-
tory effect of BMD122 on migration was greater in
laminin-treated cells (Fig. 5B). Our data suggest that
α6β4-dependent cell migration on laminin in response
to EGF is also regulated by 12-LOX.
To confirm the role of 12-LOX in β4-regulated
12(S)-HETE production and EGF-stimulated migration,
we transfected A431 cells with six different shRNA
constructs, each targeted to a unique region of the
12-LOX gene, and screened for 12-LOX knockdown
after puromycin selection. Both 12-LOX gene and protein
expression were assayed to validate the knockdown
(Fig. 6A, B). Compared to the parental and non-silencing
(ns) shRNA control cells, the #1 and #2 clones showed
decreased 12-LOX mRNA expression, as measured by
RT-PCR (Fig. 6A). None of the cells transfected with
construct #4 survived selection, and so these were not
included in the analysis. At the protein level, clone #1
appeared to lack 12-LOX compared to the parental
and ns shRNA control cells (Fig. 6B). We also analyzed
12(S)-HETE production with 3E1 stimulation, which we
demonstrated activates 12-LOX enzymatic activity
(Additional file 8a). PC-3 prostate cancer cells stably
expressing 12-LOX were used as a positive control
for 12(S)-HETE production (Fig. 6C). In both the parental
A431 and ns shRNA control cells, 3E1 stimulation re-
sulted in an increase of 12(S)-HETE production com-
pared to AA treatment alone. This response was not
seen in the #1 or #2 clones, indicating that 12-LOX
Fig. 5 The α6β4 integrin and 12-LOX activity function in EGF-induced chemotaxis. (a) Migration assay: A431 cells were pretreated with 3E1
antibody for 20 min, then plated on laminin-coated invasion plates either with or without EGF (1 ng/ml) for 3 h in the presence or absence of
pharmacological inhibitors as described in Methods. Data represent the mean number of transmigrated cells/microscopic field (± SE). The
experiments were repeated three times in triplicate. a, P < 0.01 when compared to no-EGF treated group; b, c, d, P < 0.01 when compared to
EGF treated control group. (b) Alternate migration assay: Comparison of chemotaxis of A431 cells toward EGF when stimulated with either mAb
3E1 or laminin in the presence or absence of the 12-LOX specific inhibitor BMD122. (10× magnification) (c) Controls for (b). (d) Absorbance
measurements of dye retained by transmigrated cells
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activity. Downstream of β4 stimulation and subsequent
12-LOX recruitment / enzymatic activation, 12(S)-HETE
acts back on its receptor, 12HETER1, so as to activate
MAPK signaling [32, 33, 34]. As seen in Fig. 6D, parental
and ns shRNA control cells respond to 3E1 with an
increase in ERK phosphorylation. Basal ERK activation
was higher in clone #1, which did not increase in response
to 3E1. This may be the result of compensatory survival
signaling in response to the loss of 12-LOX and its
associated pro-survival signals.
Next, we utilized the 12-LOX KD cells to confirm the
role of 12-LOX in integrin-mediated, EGF-stimulated
cell invasion (Fig. 6E). Consistent with previous results,β4 stimulation and EGF increased invasion of the
parental and ns shRNA control A431 cells and prostate
PC3-12LOX transfectants, while BMD122 dramatically
reduced invasion. The invasion of the ns shRNA cells was
increased in all conditions compared to the parental
control and could be due to non-specific targeting effects
of the scrambled shRNA. EGF stimulation lead to
marginal, if any, increased invasion in the #1 and #2
12-LOX KD cell lines. This suggests that 12-LOX
promotes EGF-stimulated invasion. Similar to the
results seen in the parental and ns shRNA cells, BMD122
reduced cell invasion in the #2 12-LOX KD that had
residual 12-LOX protein, whereas it had no effect on
the #1 12-LOX KD cells. Therefore, despite β4 stimulation,
Fig. 6 12-LOX knockdown inhibits β4-mediated 12(S)-HETE production, downstream ERK activation, and cellular invasion. (a-c) Validation of
12-LOX KD in A431 cells. (a) 12-LOX mRNA levels measured by RT-PCR in A431 parental, ns (non-silencing) shRNA control cells, and 12-LOX KD
cell lines. *p < 0.001 (b) Western blot analysis of 12-LOX protein levels in 12-LOX KD clones, ns shRNA control, parental A431, CHO (negative
control for 12-LOX expression; polyclonal platelet-type 12-LOX antibody appears to be recognizing another 12-LOX isoform in CHO cells),
PC-3 12-LOX overexpressors along (positive control for 12-LOX), 3.1 empty vector control cells, and platelet lysate (positive control for 12-LOX
expression). (c) No increase in 12(S)-HETE levels were seen with 3E1 stimulation in #1 and #2 12-LOX KD clones. 12-LOX activity was measured
by 12(S)-HETE production using LC-MS after a 6 h incubation with 3E1 and AA. (d) #1 12-LOX KD cells do not respond to 3E1 stimulation with
an increase in phosphorylated ERK levels. Western blot evaluation of phosphorylated ERK with 30 min 3E1 stimulation. Densitometry analysis
represents the ratio of phosphorylated ERK to total ERK. (e) #1 12-LOX KD cell invasion is not affected by BMD122 enzymatic inhibition of 12-LOX.
Cells were pre-treated with BMD122, then stimulated with 3E1 or EGF and allowed to invade through a Boyden Chamber insert coated with
Matrigel for 24 h. Images taken at 10 x. Invaded cells were stained with crystal violet, the dye content dissolved in 10 % acetic acid, and the
absorbance measured at OD570nm. Columns represent the invasion reported as the mean of three samples +/− SE
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12-LOX.
Discussion
The platelet-type, metabolically active, 12-LOX is upregu-
lated in a variety of tumor cell types such as Lewis lung and
rat Walker carcinoma cells. Furthermore, overexpression of12-LOX in prostate or breast cancer cells stimulates growth
in tumor xenograft models, and tumor angiogenesis [23,
35], where 12-LOX overexpression regulates HIF1α [36].
The sole metabolic product of AA metabolism by 12-LOX,
12(S)-HETE, modulates several traits related to the
metastatic potential of tumor cells. These include cell
motility [37], secretion of lysosomal proteinases cathepsins
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vasion [22, 34], expression of integrin receptor αΙIbβ3
[39], tumor cell adhesion to endothelium, and spread-
ing on subendothelial matrix [13]. The role of 12(S)-
HETE in tumor cell induced platelet activation
(TCIPA) is well-appreciated [40, 41], and additional
studies have recently identified 12-LOX as a contributing
factor to immune-mediated thrombosis [42]. 12(S)-HETE
also regulates lung colonization in vivo. This metabolite
activates downstream signaling by virtue of the cognate
receptor for 12(S)-HETE (GPR31, 12-HETER1) discovered
by our group [34]. However, until now there has been
little insight into how the activity of 12-LOX enzyme
itself is regulated.
Given that 12-LOX membrane translocation is essential
for increased activity, and that the integrin β4 subunit was
identified as an interacting protein [1], we hypothesized
that 12-LOX interaction with the cytoplasmic domain of
the β4 subunit may enhance its lipoxygenase activity,
particularly as these proteins contribute to similar cancer
phenotypes.
The enzymatic activities of 5-LOX and 15-LOX are also
increased by membrane translocation. For example,
5-LOX is predominantly cytosolic in resting neutrophils
but translocates to the nuclear membrane [43] to associate
with FLAP. Likewise, 15-LOX activity reportedly increases
in reticulocytes after membrane translocation [44].
Additional studies support that 12-LOX enzymatic activity
in rat W256, HEL, and murine B16a melanoma cells is
membrane-associated despite the protein being pre-
dominantly cytosolic [24, 45].
The integrin β4 is essential for the organization and
maintenance of epithelial architecture through formation
of hemidesmosomes that link the intermediate filament
cytoskeleton to the extracellular matrix. It is a dynamic pro-
tein that also has strong connections to tumor-associated
phenotypes such as invasion, angiogenesis, and tumor pro-
motion [46], and continues to appear in screens for genes
that are essential for regulating invasion and migration [47].
Following integrin stimulation, 12-LOX distinctly coloca-
lized with the β4 subunit, predominantly at the edge of cells
or at cell-cell junctions. 12-LOX was found localized to
cytosolic, perinuclear, and cell surface sites, and the β4
immunofluorescence staining pattern was consistent with
its known localization to hemidesmosomes on the ventral
surface or the trailing edge of adherent A431 cells
[48]. This represents the first identified protein that
directly associates with 12-LOX to perhaps scaffold it
with additional regulatory proteins residing at the cell sur-
face. The biochemical and imaging data in combination
with the 12-LOX knockdown studies provide significant
evidence for a physical association between 12-LOX and
the cytoplasmic domain of β4 that is functionally relevant
for enzymatic activity as demonstrated in the LC-MSand RP-HPLC data, where 12(S)-HETE biosynthesis was
increased following specific stimulation of β4. Importantly,
this association promotes migration in response to EGF as
a chemoattractant. As 12(S)-HETE is known to be stable,
the decline that was noted after 60 min is likely due to
esterification of the product back into the membrane and
not due to degradation.
12(S)-HETE induces a plethora of cellular responses
in tumor cells, including protection from apoptosis.
Inhibition of 12-LOX activity leads to apoptosis in
Walker 256 carcinosarcoma cells, whereas overexpression
of 12-LOX in the same cell type results in up-regulation
of the anti-apoptotic protein Bcl-2 [28], while in MCF-7
breast cancer cells, overexpression leads to increased
cellular proliferation in nude mice [35]. Similarly, addition
of exogenous 12-LOX substrate, AA, could rescue human
gastric cancer cells from apoptosis induced by serum
starvation. This rescue could be blocked by 12-LOX
inhibitors, but not by cyclooxygenase pathway inhibitors
[28]. Previously we showed that antibody ligation of β4
rescued A431 cells from apoptosis induced by plating
cells on an inappropriate growth surface, i.e., untreated
polystyrene plates [49]. Therefore, as both 12-LOX,
through its metabolite 12(S)-HETE, and β4 ligation have
demonstrable anti-apoptotic effects [49], we sought to test
the relationship between up-regulation of 12-LOX activity
and β4 ligation in relation to cell survival. As demonstrated
in the results, ligation of β4 increased resistance of A431
cells to apoptosis induced by 12-LOX inhibitor, BMD122,
which appears to support this relationship. Nevertheless,
this may not hold true in all cell types, and suggests that
the role of β4 in apoptosis may be cell-type specific. Given
the wide range of cancer promoting properties of 12-LOX
and 12(S)-HETE combined with the tumor promoting
functions of β4, targeting their interaction in cancer cells
may prove therapeutically efficacious [50]. As noted,
β4-mediated, EGF-stimulated A431 cell invasion relied
on 12-LOX activation, and the 12-LOX specific enzymatic
inhibitor, BMD122, reduced this invasion. 12-LOX
knockdown by shRNA rendered the cells un-responsive to
EGF-stimulated invasion and resistant to the effects of
BMD122. Those residues or motifs in the cytoplasmic
domain of β4, or conversely in 12-LOX that are critical
for interaction remain to be determined and make an
attractive therapeutic target.
Conclusions
In summary, we have demonstrated that our original
discovery using a yeast model of the interaction between
the cytoplasmic domain of the β4 subunit of the integrin
adhesin and the eicosanoid enzyme 12-LOX is valid, spe-
cific, and has functional consequences in mammalian cells.
With these data we have demonstrated for the first time
that these proteins interact both physically and functionally,
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eicosanoid biology. Given the existing correlation between
12-LOX and tumor progression and metastasis, the
insight from this study provides the foundation for evalu-
ating this novel interaction with the β4 integrin as a target
for intervention.Materials and methods
Antibodies and reagents
Antibodies: to human integrin β4 (mAB1964, clone 3E1;
mAB clone 450-11A) and β1 (mAB1951, clone P4G11)
subunits, Chemicon International, Inc. (Temecula, CA) of
Millipore (Billerica, MA), GIBCO BRL (Gaithersburg, MD),
or BD Biosciences/Pharmingen; to human 12-LOX, Oxford
Biomedical Research (Oxford, MI); to ERK and phosphory-
lated ERK (T202/Y204), Cell Signaling (Danvers, MA).
Alexa488 goat anti-rabbit IgG or Alexa594 goat anti-mouse
IgG were from Molecular Probes/Invitrogen (Eugene, OR).
The anti-β4 mAbs 450-11A and 439-9B were provided by
Dr. Steve Kennel (Oak Ridge National Laboratory, Oak
Ridge, TN).
Human laminin and EGF were from GIBCO BRL or
Sigma Aldrich (St. Louis, MO). The 12-LOX-selective
inhibitor, BMD122, formerly called BHPP for N-benzyl-
N-hydroxy-5-phenylpentanamide [45], was a generous
gift from Biomide Corp. (Grosse Pointe Farms, MI).
Other 12-LOX inhibitors: Baicalein, Calbiochem (San
Diego, CA); cinnamyl-3,4-dihydroxy-α-cyanocinnamate
(CDC), Biomol International, LP (Plymouth Meeting, PA).
[3H]-12-HETE standard and [14C]-AA were from NEN
Research Products (DuPont Company, Wilmington,
DE). ODS-Silica cartridges were from J.T. Baker Inc.
(Phillipsburg, NJ). FuGENE 6 Transfection Reagent
kit was from Boehringer Mannheim (Santa Cruz, CA).Cell culture and treatments
A431 and Chinese hamster ovary (CHO) cells were
obtained from the American Type Culture Collection
(Manassas, VA), and cultured as recommended. Transfec-
tants were selected and cultured in media with 300 μg/ml
Geneticin (G418; Life Technologies, Inc., Grand Island,
NY). Prostate cancer cell lines PC-3 12-LOX/3.1 have
been described previously [51].
For treatment with β4 mAb (3E1), 5 × 106 A431 cells
were grown to sub-confluence in 100 mm Petri dishes
and serum-starved overnight prior to use. Cells were
washed with PBS (3×) and stimulated with β4 antibody
for 5, 15, 30, 60 and 90 min at a concentration of 5 μg/ml
in serum-free DMEM media. For experiments where the
natural α6β4 ligand was immobilized, the dishes were
coated with laminin (10 μg/ml) and cells were subse-
quently harvested as above. Otherwise, laminin was used
at 5 μg/ml in serum-free media.Subcellular fractionation
Cells (5×106) were cultured to 80 % confluence [75-cm2
flasks; 37 °C; 5 % CO2 in DMEM containing 10 % (v/v)
FBS], rinsed (2×) with PBS buffer, and washed (2×) in
isotonic buffer (134 mM NaCl; 15 mM Tris–HCl, pH 7.6;
5 mM glucose; 1 mM EDTA; 1 mM EGTA) before
suspension in homogenization buffer (25 mM Tris–HCl,
pH 7.6; 1 mM EGTA) containing protease inhibitors.
Cells were homogenized by sonication (15 sec, 3×, 0 °C)
(Vibracell-Microtip) with intervals of 3 min. In some
experiments, homogenates were initially centrifuged at
10,000 × g (10 min; 4 °C) and the resultant supernatant
was considered cytosolic. The membrane fraction rep-
resents the pellet obtained after a one-step centrifuga-
tion of the homogenate at 100,000 × g (1 h; 4 °C). The
10,000- and 100,000 × g pellets, respectively, were rinsed
once with homogenization buffer and resuspended in
protease inhibitor-free homogenization buffer. Samples,
standardized by protein concentration, were immediately
used for SDS-PAGE.
Measurement of 12-lipoxygenase activity by LC-MS
12(S)-HETE was measured by liquid chromatography-
mass spectrometry as previously described. Cells (8×105)
were seeded into six well plates and serum-starved over-
night. The following day media was replaced with phenol
red-free RPMI media. Cells were then stimulated with 3E1
in the presence of 10 μm AA in 1 % fatty acid-free
BSA. AA untreated cells served as a control. As an
additional control, AA was incubated in wells without
cells to measure spontaneous oxidation of AA into
12(S)-HETE, and this value was subtracted from cell-
generated 12(S)-HETE values. The detailed lipid extrac-
tion protocol has been described [52]. For measurement
of 12(S)-HETE production in parental A431 cells stimu-
lated with 3E1 as a function of time, cells were incu-
bated with 3E1 for the indicated times, washed 1×
with serum-free, phenol red-free media, and finally
treated with 10 μM AA (in 1 % fatty acid-free BSA)
for 15 min. Similarly, media from 12-LOX knock
down (KD) cell lines plus control cell lines were col-
lected after 6 h incubation with AA alone, or AA
with 3E1 (added together for 6 h). 5 μL of 15-HETE-d8
was added as an internal standard to monitor extrac-
tion efficiency. Samples were clarified by centrifugation at
1877 × g for 5 min. Supernatants were subjected to solid
phase extraction using Strata-X 33 μm Polymeric
Reversed Phase columns (30 mg/1 mL; Phenomenex,
Torrance, CA), followed by elution of lipid extracts
with methanol, evaporation under a stream of nitrogen,
and reconstitution in 50 μL LC-MS grade methanol.
Ammonium acetate (50 μL, 35 mM) was added before
LC-MS analysis. Samples were analyzed as biological
triplicates.
Tang et al. Molecular Cancer  (2015) 14:111 Page 10 of 13Immunoprecipitation
Cells were lysed in cold buffer (1 % Triton X-100; 150 mM
NaCl; 10 mM Tris, pH 7.4; 1 mM EDTA; 1 mM EGTA,
pH 8.0; 0.2 mM sodium ortho-vanadate; 0.2 mM PMSF;
0.01 % aprotinin; 5 μg/ml leupeptin; 0.5 % NP-40), and
subsequently clarified (10,000 × g; 10 min). Supernatants
were immunoprecipitated with 4–6 μl of antibody against
human 12-LOX, anti-β1, or the anti-β4 subunit for 2 h,
followed by 40 μl Sepharose 4B-conjugated protein G
at 4 °C overnight. Immune complexes were washed (3×)
in lysis buffer, and used for SDS-PAGE. Whole cell lysates
were used for input controls.Western blotting
Performed as per standard techniques with horseradish
peroxidase-conjugated secondary anti-IgG diluted 1:4500,
and enhanced chemiluminescence (ECL) (both: Amersham,
Arlington Heights, IL) for detection.Expression constructs and transfection
Dr. Filippo Giancotti (Memorial Sloan-Kettering Cancer
Center, NY) kindly provided expression constructs
encoding wild-type or mutant, truncated human β4
subunits. These were engineered in the eukaryotic
expression vector pRC-CMV (Invitrogen Corp., San
Diego, CA) as described [53]; pRC-CMV-β4 (full-length
β4 subunit cDNA); pCMV-β4 Δ854-1752 (tail-less, trun-
cated β4 lacking the cytoplasmic domain); and pCMV-β4
Δ70-660 (headless, truncated β4, extracellular sequences
replaced by a c-myc epitope tag). The full-length
cDNA encoding human 12-LOX was subcloned into
the EcoRI/XbaI sites of pcDNA3.1 (Invitrogen) from
pCMV-12-LOX, gifted from Dr. Colin D. Funk (Queen’s
University, Kingston, Ontario, CA). Expression vectors of
full-length β4 and 12-LOX used neomycin as a selection
marker. As deletion constructs of β4 contained no selective
marker, they were cotransfected with neomycin encoding
vector, pcDNA3.1. Cells grown in 6-well plates were
transfected with 3–12 μg of pcDNA3.1, pCMV-β4,
pcDNA-12-LOX, pCMV-β4 tail-less or pCMV-β4
headless using the FuGENE 6 Transfection Reagent
following the manufacturer’s protocol. Neomycin-resistant
cells were selected in 300 μg/ml geneticin. Knockdown of
gene expression by shRNA was performed using Lentiviral
pGIPZ constructs targeted to unique regions of the 12-
LOX gene, which were purchased from Open Biosystems
(Rockford, IL): V2LHS_112083 (#1), V2LHS_112086 (#2),
V2LHS_112087 (#3), V3LHS_335849 (#5), V3LHS_335846
(#6), RHS4346 (#8). A431 stable transfections were achieved
with 2 μg plasmid DNA, using Lipofectamine LTX
(Invitrogen), followed 48 h later by selection in DMEM
containing 1 ug/mL puromycin for 3 weeks (Invitrogen,
Grand Island, NY). Authorization to use lenti-basedvectors for transfection was granted by the WSU Institu-
tional Biosafety Committee as protocol IBC 02-51-11.
DNA fragmentation assay
Cells (2.5×106) were grown to sub-confluence in 10 cm
tissue culture dishes and serum-starved (18 h) prior to
use. Cells were washed with PBS (3×), treated with varying
BMD122 concentrations for 24 h, and subsequently
stimulated with 3E1 antibody for 5, 15, 30, 60 and 90 min.
For DNA isolation, cells from each time point were
harvested and lysed with lysis buffer (200 μl) for 5 min,
clarified at 500 × g (5 min), and the resulting pellet was
re-extracted using 200 μl lysis buffer (2 min) and re-
clarified. Supernatants were pooled and treated with SDS
(1 %) and DNase-free RNase (5 mg/ml) (Ambion, Austin,
TX) for 2 h (56 °C), followed by proteinase K (2.5 mg/ml)
(Ambion, Austin, TX) treatment for 2 h (37 °C).
Finally, samples were extracted (1x) with alkaline phenol/
chloroform/isoamyl alcohol (25:24:1) and DNA was
precipitated with 0.3 M sodium acetate (pH 5.2) and
ethanol. DNA laddering was assayed from equal numbers
of cells, or 20 μg resolved on a 1.2 % agarose gel followed
by ethidium bromide staining.
Migration assays
Modified Boyden chambers (Becton Dickinson, Bedford,
MA) were coated with human laminin (5 μg/ml; 2 h;
25 °C) on the upper and lower surfaces, and seeded with
A431 cells (5x105/ml) in DMEM-0.1 % BSA. Antibodies
to β4 integrin were preincubated with aliquots of cells
for 20 min prior to seeding. EGF (1 ng/ml) was added to
the lower chamber as a chemoattractant. The final concen-
tration of 12-LOX pharmacological inhibitors added to the
lower chambers was: 10 μM CDC or baicalein, or 20 μM
BMD122. All conditions were tested in triplicate. After 3 h,
inserts were fixed in a Quick-Fix solution, double-stained
with hematoxylin and eosin (HE), and mounted for
observation and counting. The number of migrated
cells (12 fields × 100) was counted in a double-blind
manner. Alternately, inserts with 8 μm pores (BD Falcon;
Franklin Lakes, NJ) were coated with 100 ul of phenol
red-free, basement membrane and matrix growth
factor-reduced Matrigel (BD Bioscience, Bedford, MA)
(250 ug/ml; 1 h; 37 °C; excess liquid removed). Inserts
were seeded from confluent, serum-starved (overnight)
A431 cells (5 × 105) in 0.5 ml serum-free media. Where
noted, cells were pre-treated with 25 μM BMD122 for 1 h
prior to 30 min treatments with the following: 3E1 anti-
body (3 ug/well) or the natural ligand, laminin (10 μg/ml).
The lower chamber contained serum-free medium with
EGF (2 ng/ml), and complete media with or without serum
served as positive and negative controls, respectively. After
24 h, transmigrant cells on the underside of the insert were
stained with Azure A&B/Eosin Y using the Diff Quick
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with distilled water. After removing residual, non-migrated
cells, membranes were cut from the inserts, dissolved in
10 % acetic acid and assayed for dye content at an absorb-
ance of OD570. Results are the mean of three samples.Real-time PCR
Isolated RNA (2 μg) (NucleoSpin RNAII kit; Macherey-
Nagel, Bethlehem, PA) was reverse-transcribed (High
Capacity Reverse Transcription Kit; Applied Biosystems,
Foster City, CA) for real-time PCR (Taqman Gene
Expression Master Mix, ALOX12 (HS00167524) and
GAPDH primers; Applied Biosystems, Foster City, CA).
All sample reactions were run in triplicate on the AB 7500
Fast Real Time PCR System. Relative expression of
12-LOX was quantified by the Ct value measured against
the internal standard GAPDH using the 7500 Fast System
SDS Software v1.4.0 (Applied Biosystems).Additional files
Additional file 1: Interaction of 12-LOX with β4 by
immunoprecipitation. The density of the 12-LOX band in transfectants
was greater (S1a, right panels) than the comparable band in the
non-transfected cells (Fig. S1a, left panels).
Additional file 2: 12-LOX colocalization with β4 by laser confocal
immunofluorescence imaging. Subconfluent, serum-starved A431 cells
were treated with 5 mg/ml laminin or 3E1 for two hours, or non-specific
mouse IgG for one hour. After fixation, cells were labeled sequentially first
with P-12 LOX antibody and its respective secondary antibody followed by
the anti-b4 antibody and its secondary antibody. Primary and secondary
antibodies were used at 1:100 and 1:500, respectively. (Fig. S2a-d).
Overlapping areas of staining, which appear in yellow in the superimposed
confocal images in laminin and 3E1 stimulated cells (Fig. S2a,b) were found
around the nuclear membrane, at cell-cell junctions and at the cell periphery.
In unstimulated controls, or cells treated with mouse preimmune serum,
virtually no positive staining was observed for 12-LOX with b4 (Fig. S2c,d).
The surface staining in green in the IgG treated cells (Fig. S2d) either
represents a non-specific interaction of the secondary antibody with the IgG
used to stimulate the cells, or may represent a novel redistribution of 12-LOX
by a component of the pre-immune serum. As controls, 3E1-stimulated cells
were stained with secondary antibodies alone (Fig. S2e). While anti mouse
antibody detected 3E1, used to stimulate the cells, there was limited
costaining with the secondary antibodies alone. However, this was rare in
the observed fields, and the distribution is different from that seen in the
laminin and 3E1-stimulated cells (Fig. S2a,b, f; S3-7=.avi animated Z-stacks).
Mowiol-preserved samples were observed with a Leica TCS SP5 laser
scanning confocal microscope.
Additional file 3: Colocalization of 12-LOX and ITGB4. Animated
selection of confocal microscope Z-stack series corresponding to data
in Additional file 2.
Additional file 4: Colocalization of 12-LOX and ITGB4. Animated
selection of confocal microscope Z-stack series corresponding to data
in Additional file 2.
Additional file 5: Colocalization of 12-LOX and ITGB4. Animated
selection of confocal microscope Z-stack series corresponding to data
in Additional file 2.
Additional file 6: Colocalization of 12-LOX and ITGB4. Animated
selection of confocal microscope Z-stack series corresponding to data
in Additional file 2.Additional file 7: Colocalization of 12-LOX and ITGB4. Animated
selection of confocal microscope Z-stack series corresponding to data
in Additional file 2.
Additional file 8: Measurement of 12-lipoxygenase activity by
RP-HPLC. (A) 12(S)-HETE peak eluted with corresponding authentic
compound. (B) The data shown are the mean value (±SEM) from three
experiments as represented in (A), error bars indicate SEM. 12(S)-HETE
production was measured using reverse-phase high-performance liquid
chromatography (RP-HPLC). At designated time points, 3E1-treated A431
cells (described earlier) were harvested into homogenization buffer and
sonicated (10 sec; 2×; 0 °C). Samples were clarified by centrifugation
(10,000 × g; 10 min) and supernatants were immediately separated into
membrane and soluble fractions by centrifugation (100,000 × g; 4 °C; 1 h).
Each fraction (100,000 x g supernatants and resuspended 100,000 x g pellet)
was incubated with exogenous 14C-AA (10 μM; 37 °C; 15 min). The incubation
was terminated by acidification of the suspension to pH 3.5 with 1 N HCl.
Samples were centrifuged (2000 × g) and supernatants (cell lipids) were
extracted by the method of Benedetto and Lands [54]. Briefly, acidified
samples were applied to ODS-Silica cartridges, followed by elution of lipid
extracts with freshly redistilled ethyl acetate. These were evaporated under
a stream of nitrogen and reconstituted in acetonitrile/acetic acid (1000:1) for
HPLC analysis using chromatography conditions based on methods of Powell
and Liu. Reverse-phase HPLC was performed using a Beckman Ultrasphere
C18-ODS column (4.6 × 250 mm; 5 μm) (Beckman, Fullerton, CA) with a
Vista 5500 pump system (Varian, Palo Alto, CA). Lipoxygenase metabolites of
AA were resolved in an isocratic solvent system of acetonitrile/water/acetic
acid [54:46:0.05] at 1.5 ml/min. Column effluent was continuously monitored
with a Varian 2550 UV/Vis spectrophotometer (Varian) set at 236 nm and a
radioisotope flow detector (β-RAM, IN/US, Fairfield, NJ). The lipoxygenase
metabolites were identified based on the retention time of the authentic
compounds. [3H]-12(S)-HETE was used to confirm the identity of the peak
in the sample.
Additional file 9: Detection of nucleosomes in the cytoplasm of
cells treated with BMD122. A431 cells were exposed for 48 h to
different concentrations of BMD122. After cell lysis and centrifugation, the
cytoplasmic fractions were prediluted 1:10 with incubation buffer and
tested for nucleosomes by ELISA. Substrate reaction time: 15 min.
Additional file 10: BMD122 effects on A431 cell survival by Trypan
blue exclusion assay. The maximum cell killing (i.e., the lowest cell
survival) was noticed at 100 μM BMD122. The treatment was 48 h, and
the results are expressed as % cell survival compared to ethanol control
(i.e., 0 mM BMD122). Each condition was run in triplicate, and the results
were derived from the mean +/− SE of three independent experiments.
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